

### Remarks

In the Office Action dated November 14, 2007, the Examiner noted some irregularities concerning the correspondence between the U.S. application and the German priority application. The U.S. application is based upon the test of the German language PCT application. Claims have been amended to reflect the scope of disclosure in the German priority document.

At page 3, item 3, of the Office Action, the Examiner has presented a listing of terms allegedly not disclosed in the priority document. Applicant specifically disputes:

- a) Antibiotic compounds, which are disclosed at page 8, lines 10-11 (antimycotics amphotericin B and derivatives);
- b) Analgesic compounds, which are disclosed at page 8, lines 6-8 (acetylsalicylic acid, ibuprofen);
- c) Virostatic compounds, which are disclosed at page 6, line 119 (methotrexate and 5-fluorosil).

Furthermore, the use of the medicaments is disclosed for the treatment of mammals at page 21, third line from the bottom (Balb/c mice).

These utilities have not been withdrawn.

Claims 38 and 42 have been renumbered to be consistent with the renumbered claims per the Office Action dated July 6, 2007 in the expectation that a previous restriction requirement should be withdrawn.

In view of these amendments, it is submitted that the claims now pending are fully supported by the priority document and are entitled to allowance over the inventor's own parallel publication.

Respectfully submitted,



Joseph Guy  
Registration No 35,172  
Agent for Applicant  
Customer No.: 46591